**
In a significant advancement for cancer care, NHS England has announced the rollout of a new injectable formulation of Keytruda, a leading immunotherapy drug. This innovative treatment is expected to substantially reduce the time patients spend in hospitals, allowing them to receive vital therapy in a matter of minutes rather than hours. The change is set to benefit thousands of patients across the UK, enhancing their treatment experience and providing them with more time for their daily lives.
A Transformative Treatment Option
Shirley Xerxes, an 86-year-old resident of St Albans, Hertfordshire, was among the first to benefit from this new method at the Mount Vernon Cancer Centre near Watford. Previously, patients received Keytruda through an intravenous infusion that could take over an hour to administer. Xerxes expressed her relief at the new treatment, stating, “I was in the chair for a matter of minutes instead of an hour or more. It’s made such a difference and gives me more time to live my life, including spending more time gardening.”
Approximately 14,000 patients in England begin a course of Keytruda, also known as pembrolizumab, each year. With the introduction of this injectable version, many of these individuals will likely transition to the quicker administration method. Currently, Keytruda is used to treat various cancers, including lung, head and neck, cervical, and breast cancers.
Streamlined Administration and Benefits
The injectable form of Keytruda will be administered every three weeks as a one-minute injection or every six weeks as a two-minute injection, depending on the patient’s specific diagnosis. This new approach not only streamlines the administration process but also promises to alleviate some of the strain on hospital resources. Professor Peter Johnson, NHS England’s national clinical director for cancer, highlighted the significance of this development, stating, “Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals.”
This injectable option is the third of its kind to be introduced within the NHS, following the rollout of a similar treatment, Opdivo (nivolumab), in certain hospitals last year.
Immunotherapy: A Game Changer in Cancer Treatment
Immunotherapy represents a groundbreaking approach to cancer treatment, working by enabling the body’s immune system to better recognise and destroy cancer cells. Cancer cells often employ mechanisms to evade the immune response, effectively hiding from detection. Immunotherapy drugs like Keytruda help to counteract this by blocking signals that inhibit immune activity, thus making cancer cells more visible to the immune system.
Keytruda has been a pioneer in this field, first gaining approval for skin cancer and subsequently being used for various other malignancies. It is now considered one of the best-selling prescription drugs globally, with projected worldwide sales of $30 billion (£22 billion) by 2025.
Future Implications for Cancer Care
The financial specifics of the NHS’s deal with Merck Sharp & Dohme (MSD), the manufacturer of Keytruda, remain confidential. However, it is believed that the NHS will pay a similar price for both the intravenous and injectable forms of the drug. Since its launch over a decade ago, Keytruda has generated estimated sales of $180 billion, making it one of the most commercially successful medicines in history.
As patents protecting the original formulation are set to expire in the coming years, the potential for generic alternatives to enter the market may arise, offering more affordable options for patients in the future. Critics in the US have raised concerns about MSD’s strategy, suggesting that the introduction of the injectable form could serve to shield it from competition.
Why it Matters
The introduction of this injectable version of Keytruda marks a pivotal moment in cancer treatment within the NHS, promising not only to enhance patient comfort and convenience but also to potentially reshape the landscape of cancer care. By decreasing the time patients spend in hospital, this innovation could lead to more efficient use of NHS resources, ultimately improving patient outcomes and quality of life. As the healthcare system adapts to these advancements, the hope is that more patients will experience the benefits of rapid, effective treatment in a supportive environment.
